Analyst Ratings for CytomX Therapeutics (CTMX)
CTMX Rating Summary
CTMX Price Target Summary
- Highest: $3.25 (BMO Capital)
- Lowest: $2.50 (Jefferies)
- Average: $2.92
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$2.92 (+74.7%)
* Over Last 12-Mos
Rating Score: 4.1 / 10
Percentile Rank: 41%
Avg. $ Target:
$2.92 (+74.7%)
* Over Last 12-Mos
Rating Score: 4.1 / 10
Percentile Rank: 41%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/8/2023 | Wedbush | Robert Driscoll | Upgrade | Outperform (Neutral) |
3.00 (2.00) |
1.28 (1.67) |
30.47% | Details |
| 11/14/2022 | BMO Capital » Updated 3/12/2024 |
Etzer Darout | Downgrade | Market Perform (Outperform) |
3.25 (3.30) |
1.29 (1.67) |
29.46% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
